Information on CGD2
Basic details
Name: Granulomatous disease, chronic, 2 | Acronym: CGD2
Alt. names:
Gene: NCF2 | MOI: Autosomal recessive | Mechanism of action:
No. of cases in DB: 0 | First reported in: 1995
Last updated on: 2023-02-28 16:41:18 by
Description
Surveillance for infections and infectious complications is indicatred, and preventive measures (eg, antibacterial/antifungal prophylaxis, interferon gamma) may be beneficial; To treat fungal infections, specific antifungal drugs may be beneficial, and longer treatment courses (as well as specific considerations including coadministration with corticosteroids) may be indicated in individuals with CGD; In some instances, HSCT may be beneficial; Certain agents should be avoided, including material that would allow fungal spore inhalation. Refs. PMIDs: 2770793; 7795241; 10498624; 11060536; 22157170; 22876374; 23264412
Management
Description of management option has not been reviewed yet.
Please mind that full curation of this condition has not started yet. Please contact us if you want to volunteer.
0 reported cases added to GenIA
| SubjectID | Sex | Fam.ID | AD | AFM | Validity | Country | Population | Reference & Pub.code |
|---|
AD: Age at genetic diagnosis; AFM: age at first manifestation; PMID: PubMed ID; GRID: GenIA reference ID (ref. not in PubMed).
Summary of clinical findings
[Considering only Definitive and Possible cases]
| Rank | Clinical term | Present | Absent | Unreported |
|---|---|---|---|---|
| 1 | Impaired oxidative burst |
7 (99.9%) | 0 (0.0%) | 0 (0.0%) |
| 2 | Infantile onset |
4 (66.7%) | 0 (0.0%) | 2 (33.3%) |
| 3 | Childhood onset |
3 (42.9%) | 0 (0.0%) | 4 (57.1%) |
| 4 | Recurrent abscess formation |
3 (99.9%) | 0 (0.0%) | 0 (0.0%) |
| 5 | Recurrent infections |
2 (99.9%) | 0 (0.0%) | 0 (0.0%) |
| 6 | Axillary Lymphadenopathy |
1 (99.9%) | 0 (0.0%) | 0 (0.0%) |
| 7 | Cervical lymphadenopathy |
1 (99.9%) | 0 (0.0%) | 0 (0.0%) |
| 8 | Oral candidiasis |
1 (14.3%) | 0 (0.0%) | 6 (85.7%) |
| 9 | Failure to thrive |
1 (25.0%) | 0 (0.0%) | 3 (75.0%) |
| 10 | Inflammation of the large intestine |
1 (99.9%) | 0 (0.0%) | 0 (0.0%) |
| 11 | Liver abscess |
1 (16.7%) | 0 (0.0%) | 5 (83.3%) |
| 12 | Lung abscess |
1 (14.3%) | 0 (0.0%) | 6 (85.7%) |
| 13 | Mediastinal lymphadenopathy |
1 (99.9%) | 0 (0.0%) | 0 (0.0%) |
| 14 | Osteomyelitis |
1 (14.3%) | 0 (0.0%) | 6 (85.7%) |
| 15 | Perianal Abscess |
1 (14.3%) | 0 (0.0%) | 6 (85.7%) |
| 16 | Peritonitis |
1 (25.0%) | 0 (0.0%) | 3 (75.0%) |
| 17 | Pulmonary nodule |
1 (99.9%) | 0 (0.0%) | 0 (0.0%) |
| 18 | Impetigo |
1 (14.3%) | 0 (0.0%) | 6 (85.7%) |
| 19 | Recurrent urinary tract infections |
1 (14.3%) | 0 (0.0%) | 6 (85.7%) |
Please mind that full curation of this condition has not started yet. Please contact us if you want to volunteer.
Summary of treatment outcomes
[Considering only Definitive and Possible cases]
| Treatment ⓘ | Responses & clinical indications |
|---|
Please mind that full curation of this condition has not started yet. Please contact us if you want to volunteer.